Bortezomib
Showing 1 - 25 of 1,116
Bortezomib, Acute Myeloid Leukemia Trial in Wuhan (DAG pre-excitation regimen with Bortezomib)
Recruiting
- Bortezomib
- Acute Myeloid Leukemia
- DAG pre-excitation regimen with Bortezomib
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Jul 31, 2023
Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Bortezomib)
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- Bortezomib
-
Salt Lake City, UtahHuntsman Cancer Institute/University of Utah
Sep 7, 2023
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia With Failed Remission
- Bortezomib
-
São Paulo, SP, BrazilInstituto do Cancer do Estado de Sao Paulo
Sep 12, 2023
Rheumatoid Arthritis Trial in Beijing (bortezomib)
Not yet recruiting
- Rheumatoid Arthritis
- bortezomib
-
Beijing, ChinaPeking Union Medical College Hospital
Apr 6, 2023
Alvocade® (Bortezomib) Safety and Effectiveness Study
Completed
- Multiple Myeloma, Refractory
- Bortezomib
- (no location specified)
Aug 19, 2023
Immunoglobulin Light-chain Amyloidosis Trial (Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules
Not yet recruiting
- Immunoglobulin Light-chain Amyloidosis
- Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab
- Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab
- (no location specified)
Mar 18, 2023
Bortezomib, Glomerulonephritis, MN Trial in Shanghai (Bortezomib)
Recruiting
- Bortezomib
- +5 more
- Bortezomib
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Oct 28, 2022
Getting Peripheral Neuropathy in Patients Treated With
Not yet recruiting
- Chemotherapy-induced Peripheral Neuropathy
- (no location specified)
Mar 23, 2023
Bone Marrow Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult Trial in Indianapolis
Not yet recruiting
- Bone Marrow Transplant Complications
- +4 more
- Sitagliptin
- +2 more
-
Indianapolis, IndianaIndiana University Melvin and Bren Simon Comprehensive Cancer Ce
May 30, 2023
Multiple Myeloma, Renal Failure Trial in Augusta (Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide,
Not yet recruiting
- Multiple Myeloma
- Renal Failure
- Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
-
Augusta, GeorgiaGeorgia Cancer Center-Augusta University
Nov 16, 2023
Multiple Myeloma Trial in Hackensack (Thalidomide+Melphalan +Bortezomib+stem cell transplant)
Completed
- Multiple Myeloma
- Thalidomide+Melphalan +Bortezomib+stem cell transplant
-
Hackensack, New JerseyJohn Theurer Cancer Center at Hackensack University Medical Cent
Dec 16, 2022
Waldenstrom's Macroglobulinemia Trial in Houston (Bortezomib, Rituximab, Valacyclovir)
Active, not recruiting
- Waldenstrom's Macroglobulinemia
- Bortezomib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 5, 2022
Multiple Myeloma, Monoclonal Gammopathy of Renal Significance Trial in United States (Cyclophosphamide, Bortezomib,
Recruiting
- Multiple Myeloma
- Monoclonal Gammopathy of Renal Significance
- Cyclophosphamide
- +3 more
-
Basking Ridge, New Jersey
- +6 more
Oct 16, 2023
Newly Diagnosed Multiple Myeloma Trial in New York (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- Newly Diagnosed Multiple Myeloma
- Daratumumab
- +4 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Dec 29, 2022
Relapsed/Refractory Immune Thrombocytopenia Trial in Seoul (Bortezomib)
Not yet recruiting
- Relapsed/Refractory Immune Thrombocytopenia
- Bortezomib
-
Seoul, Korea, Republic of
- +1 more
Oct 30, 2022
Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)
Active, not recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Jan 10, 2023
Multiple Myeloma, Myeloma Multiple, Myeloma Trial in Poitiers (Drug and medical device)
Not yet recruiting
- Multiple Myeloma
- +2 more
- Drug and medical device
-
Poitiers, FranceCHU Poitiers
Jun 1, 2023
Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca Trial run by the National Heart, Lung, and Blood Institute
Completed
- Chronic Myeloid Leukemia (CML)
- +4 more
- Bortezomib
- NK cells
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 31, 2022
Multiple Myeloma Trial in Hackensack (Bortezomib)
Terminated
- Multiple Myeloma
- Bortezomib
-
Hackensack, New JerseyThe Cancer Center at Hackensack University Medical Center
Jun 24, 2022
Light Chain Deposition Disease, Primary Systemic Amyloidosis Trial in Canada, United States (pomalidomide, bortezomib,
Active, not recruiting
- Light Chain Deposition Disease
- Primary Systemic Amyloidosis
- pomalidomide
- +3 more
-
Denver, Colorado
- +4 more
Jan 20, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Bortezomib, Metformin Hydrochloride,
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +2 more
-
Jacksonville, Florida
- +1 more
Jan 5, 2023
Daratumumab in Combination With Bortezomib, Thalidomide, and
Not yet recruiting
- Newly Diagnosed Multiple Myeloma
- Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
- (no location specified)
Sep 27, 2022
Solid Tumor, Urethral Cancer Trial in Houston (Bortezomib, Gemcitabine, Doxorubicin)
Active, not recruiting
- Solid Tumor
- Urethral Cancer
- Bortezomib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 22, 2022
Diffuse Large B Cell Lymphoma Trial in Berlin (Ibrutinib and Bortezomib + R-CHOP)
Active, not recruiting
- Diffuse Large B Cell Lymphoma
- Ibrutinib and Bortezomib + R-CHOP
-
Berlin, GermanyCharité - Universitätsmedizin Berlin, Hematology, Oncology and T
Aug 10, 2022